Details of Disease

General Information of Disease (ID: DISKYOX0)

• Disease Name: Clostridium infection
• Synonyms: commensal infection, Clostridium; commensal infections, Clostridium; Clostridium infection; infections, Clostridium; infection, Clostridium; commensal Clostridium infection
• Disease Class: 1A04: Clostridium difficile enterocolitis
• Definition: Infections with bacteria of the genus clostridium.
• Disease Hierarchy:
  DIS0O0AU: Anaerobic bacteria infectious disease
  DISZ44JH: Gram-positive bacterial infection
  DISEM33Q: Infectious disease
  DISKYOX0: Clostridium infection
• ICD Code:
  ICD-11: ICD-11: 1A04
  ICD-10: ICD-10: A04.7

Drug-Interaction Atlas (DIA) of This Disease

This Disease is Treated as An Indication in 6 Approved Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Botulism immune globulin	DMZ2YY1	Approved	NA	[1]
Diphtheria-tetanus vaccine	DM0FSIM	Approved	Vaccine	[2]
Tetanus immune globulin	DMQ45AF	Approved	NA	[1]
Tetanus toxoid	DMY90RN	Approved	NA	[1]
VA-DIFTET	DMT4KED	Approved	NA	[1]
Vax-TET	DMC7AFS	Approved	NA	[1]

This Disease is Treated as An Indication in 22 Clinical Trial Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Clostridium difficile toxoid vaccine	DM2TWKW	Phase 3	NA	[3]
GC-1107	DMP4AF0	Phase 3	NA	[4]
MK-3415A	DMGNHC2	Phase 3	Antibody	[5]
PF-06425090	DMLTDZJ	Phase 3	NA	[3]
SER-109	DMEAH7A	Phase 3	NA	[6]
SYNSORB-Pk	DMCOCQL	Phase 3	NA	[7]
ACAM-Cdiff	DMH5LHV	Phase 2	Vaccine	[8]
CP101	DM8X5Q1	Phase 2	Small molecular drug	[9]
Ibezapolstat	DMMRAKQ	Phase 2	Small molecular drug	[10]
LFF571	DMPDCIY	Phase 2	NA	[11]
MGB-BP-3	DMPBTVK	Phase 2	Small molecular drug	[12]
Oral human gammaglobulin	DMS4JA4	Phase 2	NA	[13]
Recombinant Clostridium botulinum A/B vaccine	DMI5462	Phase 2	NA	[14]
VE303	DMJD1TN	Phase 2	Live biotherapeutic product	[15]
VLA84	DM21KYH	Phase 2	Vaccine	[3]
IMM-529	DMMXEHP	Phase 1/2	Antibody	[16]
CRS-3123	DM8OWRP	Phase 1	NA	[17]
DS-2969	DMNDGPT	Phase 1	Small molecular drug	[18]
GSK2904545A	DM4SU6W	Phase 1	Vaccine	[19]
NVB-302	DM5P9OE	Phase 1	Peptide	[20]
RBX7455	DMZMEWF	Phase 1	Live biotherapeutic product	[21]
XOMA-3AB	DMK0AW6	Phase 1	Antibody	[22]

This Disease is Treated as An Indication in 3 Discontinued Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Diffistat-G	DM3WUML	Discontinued in Phase 2	NA	[23]
OPHD-001	DMB7HT4	Discontinued in Phase 1	NA	[24]
Tetanus vaccine	DMQ3SA5	Terminated	NA	[26]

This Disease is Treated as An Indication in 1 Preclinical Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
ETX-1153c	DMA4MNY	Preclinical	NA	[25]

This Disease is Treated as An Indication in 6 Investigative Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
AKT-10081	DM8UU3S	Investigative	NA	[27]
Anti-Clostridium difficile mabs	DMG6TTC	Investigative	Monoclonal antibody	[27]
Anti-Clostridium perfringens toxin mabs	DMUU3K3	Investigative	Monoclonal antibody	[27]
MNT-02-07	DMEXC6B	Investigative	NA	[27]
PT2.0	DMRKKQW	Investigative	NA	[27]
VLCA- 04	DM46KZ1	Investigative	NA	[27]

Molecular Interaction Atlas (MIA) of This Disease

References

• [1] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [2] 2006 drug approvals: finding the niche. Nat Rev Drug Discov. 2007 Feb;6(2):99-101.
• [3] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [4] ClinicalTrials.gov (NCT02361866) To Evaluate the Effectiveness(Immunogeneicity) and Safety of 'GC1107' Administered Intramuscularly in Healthy Adults. U.S. National Institutes of Health.
• [5] ClinicalTrials.gov (NCT01513239) A Study of MK-6072 and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-002). U.S. National Institutes of Health.
• [6] ClinicalTrials.gov (NCT03183141) ECOSPOR IV: An Open-Label Extension of Study SERES-012 and Open-Label Program for Evaluating SER-109 in Subjects With Recurrent Clostridioides Difficile Infection (RCDI) (ECOSPORIV). U.S. National Institutes of Health.
• [7] ClinicalTrials.gov (NCT00004465) Phase III Randomized Study of SYNSORB Pk in Children With E. Coli-Associated Hemolytic Uremic Syndrome. U.S. National Institutes of Health.
• [8] ClinicalTrials.gov (NCT00772343) Study of a Clostridium Difficile Toxoid Vaccine (ACAM-CDIFF in Subjects With Clostridium Difficile Infection. U.S. National Institutes of Health.
• [9] ClinicalTrials.gov (NCT03497806) Open-Label Extension of CP101 Trials Evaluating Oral Full-Spectrum Microbiota (CP101) in Subjects With Recurrence of Clostridium Difficile Infection (PRISM-EXT). U.S. National Institutes of Health.
• [10] ClinicalTrials.gov (NCT04247542) ACX-362E [Ibezapolstat] for Oral Treatment of Clostridioides Difficile Infection. U.S. National Institutes of Health.
• [11] ClinicalTrials.gov (NCT01232595) Safety and Efficacy of Multiple Daily Dosing of Oral LFF571 in Patients With Moderate Clostridium Difficile Infections. U.S. National Institutes of Health.
• [12] ClinicalTrials.gov (NCT03824795) Study to Assess Safety, Tolerability and Efficacy of Incremental Doses of MGB-BP-3 in Patients With CDAD. U.S. National Institutes of Health.
• [13] ClinicalTrials.gov (NCT00110708) Safety and Efficacy Study in the Treatment of Intestinal Problems Associated With Autism. U.S. National Institutes of Health.
• [14] ClinicalTrials.gov (NCT01701999) Safety, Tolerability, and Immunogenicity Study of Investigational Recombinant Botulinum Vaccine A/B (rBV A/B) in Volunteers Previously Immunized With Investigational Pentavalent Botulinum Toxoid. U.S. National Institutes of Health.
• [15] ClinicalTrials.gov (NCT03788434) Phase 2 Study of VE303 for Prevention of Recurrent Clostridium Difficile Infection (CONSORTIUM). U.S. National Institutes of Health.
• [16] ClinicalTrials.gov (NCT03065374) Treatment for Clostridium-difficile Infection With IMM529. U.S. National Institutes of Health.
• [17] ClinicalTrials.gov (NCT01551004) Phase I Trial of a Single Dose of CRS3123. U.S. National Institutes of Health.
• [18] In Vitro and In Vivo Activities of DS-2969b, a Novel GyrB Inhibitor, against Clostridium difficile. Antimicrob Agents Chemother. 2018 Mar 27;62(4):e02157-17.
• [19] ClinicalTrials.gov (NCT04026009) Study of GlaxoSmithKline's (GSK) Clostridium Difficile Vaccine to Investigate the Safety and Ability to Provoke an Immune Response in the Body When Administered in Healthy Adults Aged 18-45 Years and 50-70 Years. U.S. National Institutes of Health.
• [20] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800030483)
• [21] ClinicalTrials.gov (NCT02981316) Treatment of Recurrent Clostridium Difficile Infection With RBX7455. U.S. National Institutes of Health.
• [22] ClinicalTrials.gov (NCT01357213) Phase 1 PK Study of XOMA 3AB. U.S. National Institutes of Health.
• [23] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800008865)
• [24] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800011558)
• [25] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800025614)
• [26] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800008303)
• [27] The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954.